Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatry Investig. 2008 Jun;5(2):102-5. doi: 10.4306/pi.2008.5.2.102. Epub 2008 Jun 30.

Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder.

Author information

1
Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.

Abstract

OBJECTIVE:

We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.

METHODS:

A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).

RESULTS:

There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.

CONCLUSION:

Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

KEYWORDS:

Antimanic agents; Bipolar disorder; Dysbindin; Pharmacogenetics

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Korean Neuropsychiatric Association Icon for PubMed Central
    Loading ...
    Support Center